JP2020514301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020514301A5 JP2020514301A5 JP2019537110A JP2019537110A JP2020514301A5 JP 2020514301 A5 JP2020514301 A5 JP 2020514301A5 JP 2019537110 A JP2019537110 A JP 2019537110A JP 2019537110 A JP2019537110 A JP 2019537110A JP 2020514301 A5 JP2020514301 A5 JP 2020514301A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- domain monomer
- monomer
- polypeptide
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443523P | 2017-01-06 | 2017-01-06 | |
| US62/443,523 | 2017-01-06 | ||
| PCT/US2018/012689 WO2018129397A1 (en) | 2017-01-06 | 2018-01-05 | Compositions and methods related to engineered fc-antigen binding domain constructs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514301A JP2020514301A (ja) | 2020-05-21 |
| JP2020514301A5 true JP2020514301A5 (cg-RX-API-DMAC7.html) | 2021-02-18 |
Family
ID=62791385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537110A Pending JP2020514301A (ja) | 2017-01-06 | 2018-01-05 | 改変されたFc抗原結合ドメイン構築体に関する組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200040084A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3565595A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020514301A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018205272A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3049426A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019124709A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018129397A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112912103B (zh) * | 2018-05-21 | 2025-08-29 | 广州邦定生物技术有限公司 | 多价蛋白质复合物 |
| US20210317227A1 (en) * | 2018-07-11 | 2021-10-14 | Momenta Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS |
| CN113164591A (zh) * | 2018-07-11 | 2021-07-23 | 动量制药公司 | 与工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
| MX2021000288A (es) * | 2018-07-11 | 2021-09-08 | Momenta Pharmaceuticals Inc | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. |
| CA3106254A1 (en) * | 2018-07-11 | 2020-01-16 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs |
| JP7476219B2 (ja) | 2019-02-26 | 2024-04-30 | ピエリス ファーマシューティカルズ ゲーエムベーハー | Cd137およびgpc3に特異的な新規融合タンパク質 |
| CN111909268B (zh) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用 |
| EP4031166A1 (en) * | 2019-09-18 | 2022-07-27 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38 |
| WO2021189006A1 (en) * | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
| KR102963172B1 (ko) * | 2021-10-22 | 2026-05-18 | 상트네어바이오사이언스 주식회사 | 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| WO2024219897A1 (ko) | 2023-04-21 | 2024-10-24 | 상트네어바이오사이언스 주식회사 | 두 개의 fab 도메인 및 두 개의 fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도 |
| TW202504932A (zh) | 2023-04-21 | 2025-02-01 | 南韓商百歲生命科學股份有限公司 | 包含兩個fc區域之抗原結合蛋白及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090304715A1 (en) * | 2006-03-03 | 2009-12-10 | Tokyo University Of Science | Modified antibodies with enhanced biological activities |
| WO2008137382A1 (en) * | 2007-04-30 | 2008-11-13 | Centocor, Inc. | Anti-tissue factor antibodies and compositions with enhanced effector function |
| WO2012116926A1 (en) * | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Antigen binding proteins |
| PH12014500220A1 (en) * | 2011-07-27 | 2019-03-22 | Glaxo Group Ltd | Anti-vegf single variable domains fused to fc domains |
| SG11201506451UA (en) * | 2013-03-06 | 2015-09-29 | Merrimack Pharmaceuticals Inc | Anti-c-met tandem fc bispecific antibodies |
| US10858417B2 (en) * | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| SG10201913507SA (en) * | 2014-05-02 | 2020-02-27 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
-
2018
- 2018-01-05 US US16/474,572 patent/US20200040084A1/en not_active Abandoned
- 2018-01-05 EP EP18735797.5A patent/EP3565595A4/en not_active Withdrawn
- 2018-01-05 JP JP2019537110A patent/JP2020514301A/ja active Pending
- 2018-01-05 WO PCT/US2018/012689 patent/WO2018129397A1/en not_active Ceased
- 2018-01-05 AU AU2018205272A patent/AU2018205272A1/en not_active Abandoned
- 2018-01-05 CA CA3049426A patent/CA3049426A1/en not_active Abandoned
- 2018-01-05 RU RU2019124709A patent/RU2019124709A/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508655A5 (cg-RX-API-DMAC7.html) | ||
| RU2019124709A (ru) | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА | |
| JP2018046872A5 (cg-RX-API-DMAC7.html) | ||
| JP2020531438A5 (ja) | Nkg2d、cd16、およびhla−eに結合するタンパク質 | |
| JP2016505556A5 (cg-RX-API-DMAC7.html) | ||
| JP2020022482A5 (cg-RX-API-DMAC7.html) | ||
| ES2533963T3 (es) | Composiciones farmacéuticas dirigidas a receptores Erb-B1 | |
| JP2021532085A5 (cg-RX-API-DMAC7.html) | ||
| JP2022545647A5 (cg-RX-API-DMAC7.html) | ||
| JP2022507487A5 (cg-RX-API-DMAC7.html) | ||
| JP2023538945A5 (cg-RX-API-DMAC7.html) | ||
| JP2023507729A5 (cg-RX-API-DMAC7.html) | ||
| JP2021515798A5 (cg-RX-API-DMAC7.html) | ||
| IL299221A (en) | Cd3 binding antibodies | |
| RU2010149746A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| RU2014100111A (ru) | МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| RU2013141956A (ru) | Антитело против ксф-1r | |
| JP2018507188A5 (cg-RX-API-DMAC7.html) | ||
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| JP2010523592A5 (cg-RX-API-DMAC7.html) | ||
| RU2017129236A (ru) | Мультивалентные молекулы, содержащие dr5-связывающие домены | |
| CO6290705A2 (es) | Anticuerpos monoclonales aislados o porciones de union a antigenos, que se unen especificamente a la integrina alfa 5-beta1, y composiciones farmaceuticamente aceptables de los mismos | |
| JP2024512135A5 (cg-RX-API-DMAC7.html) | ||
| JP2019528694A5 (cg-RX-API-DMAC7.html) | ||
| JP2011526249A5 (cg-RX-API-DMAC7.html) |